Colleen Danielson, NP

Panelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.

Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent chronic graft-versus-host disease (cGVHD), highlighting its potential in challenging cases.

Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease (cGVHD), exploring its role in advancing treatment when earlier options have been exhausted.

Panelists discuss how to effectively manage the safety profile of ruxolitinib when used in the treatment of chronic graft-versus-host disease, addressing potential adverse effects and monitoring strategies.

Panelists discuss how ruxolitinib has demonstrated efficacy as a second-line treatment strategy for chronic graft-versus-host disease, reviewing the available data on its effectiveness.

Panelists discuss how chronic graft-versus-host disease severity can be stratified to guide the tailoring of systemic treatments and supportive care strategies for optimal patient management.

Panelists discuss how a case study illustrates the multisystem manifestations of chronic graft-versus-host disease and demonstrate the application of NIH organ-specific scoring for comprehensive assessment.

Panelists discuss how chronic graft-versus-host disease manifests across multiple organ systems and the diagnostic criteria used to identify and assess its various presentations.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.

The panel debates the various treatment options and comments on when they prefer each one.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

Clinical experiences with belusmosudil are shared among the panel.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

The group discusses treatment goals and patient education for chronic GVHD.

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

The panelists share their insights on the identification of patients at high risk for GVHD.

Dr Chen presents statistics on the incidence of chronic graft versus host disease.

Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.